
    
      All subjects will be treated with teriparatide (human, recombinant PTH[1-34])(human,
      recombinant PTH[1-34]), 20 microgram subcutaneously daily for 12 months. Subjects will
      consist of 290 postmenopausal women previously treated with either risedronate or alendronate
      for at least 24 months. An approximately equal number of subjects will have been previously
      treated with risedronate and alendronate, and the subjects will be balanced with regard to
      duration of previous treatment.
    
  